Search results
-
EHA 2024 preview – Novartis doubles up
… Anti-BCMA Car-T S207 Ph1 results, last updated at ASH 2023 Bristol Myers Squibb Golcadomide … Nurix NX-5948 BTK degrader S155 Had data at ASH 2023 BeiGene BGB-16673 BTK degrader S157 Had data at ASH 2023 Kymera KT-333 Stat3 degrader …
- 05/20/2024 - 18:11 -
Innate gets a new lacutamab blow
… KIR3DL2 expressing) Ph2 Tellomak Final data at ASH 2023: 38% ORR in 56 pts Innate to submit Sézary and …
- 03/21/2024 - 15:43 -
Takeda ploughs a lonely CD38 furrow
… Biosciences China ph2 * uncontrolled trial, data at ASH 2023; China ph2 * placebo-controlled trial completes …
- 06/24/2024 - 11:58 -
After Dreamm-7, how about more multiple myeloma conjugates?
… Pharma/ Huadong Medicine $20m Asia deal; ph1 data at ASH 2023, 0% ORR in 12 patients Ispectamab …
- 02/13/2024 - 14:31 -
Gilead deals more checkpoint disappointment
… HLA-G-targeting CIR-NK cells Preclinical data at SITC & ASH 2023 AR087 Y Biologics Anti-HLA-G MAb …
- 02/12/2024 - 10:40 -
A cancer pipeline cull from AbbVie
… the latter, also on top of Jakafi, didn’t impress at ASH 2023. And the SHP inhibitor JAB-3312, originated by …
- 02/06/2024 - 13:49 -
Car-T comes full circle
… (10/50 pts) in ph1/2 Transcend CLL 004 *, presented at ASH 2023 GLPG5201 Galapagos Autologous … 57% CRR (8/14 pts) in ph1 portion, presented at ASH 2023 Cemacabtagene ansegedleucel Allogene … recent data from the Transcend CLL 004 trial, presented at ASH 2023, showed a 20% complete response rate among a …
- 01/19/2024 - 16:00 -
Merck’s latest move is in bispecifics
… The latest update from a phase 1 study of the project, at ASH 2023, found a 63% response rate in relapsed/refractory …
- 06/19/2024 - 16:48 -
A new order in BTK inhibition
… one responder had a C481S BTK mutation Source: ASH 2023. Conferences Trial …
- 01/02/2024 - 15:04 -
ASH 2023 – Sympatico gives Imbruvica a second chance
ASH 2023 – Sympatico gives Imbruvica a second chance …
- 12/15/2023 - 13:39
